The consensus price target hints at a 123.3% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...

Leonard E. Post, a director at CG Oncology Inc. (NASDAQ:CGON), reported the sale of company shares valued at $34,541, according to a recent SEC filing. The transactions took place... SCHAUMBURG, Ill.

"We are thrilled to partner with AbbVie, a global leader in delivering transformative medicines in oncology and immunology, as we aim to tackle some of the most challenging and valuable targets ...

AbbVie and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets ...

WASHINGTON – Daviess Community Hospital (DCH) has established a cherished tradition to honor local nurses who have passed ...

Another potential rival - CG Oncology's retostimogene grenadenorepvec - is in phase 3 for BCG-unresponsive NMIBC. J&J is still hopeful of finding a role for TAR-200 in the smaller indication of ...

After hours: January 21 at 5:18:43 p.m. EST ...

On Tuesday, Morgan Stanley (NYSE:MS) initiated coverage on CG Oncology (NASDAQ:CGON) with an Overweight rating and a price target of $55.00. The firm highlighted CG Oncology's ...

In a tradition of deep reverence and respect, Daviess Community Hospital (DCH) proudly coordinates a Nurse Honor Guard to pay tribute to area nurses who have passed away. This solemn ...

Aa Aaaaaaaaaaa Aa 33.200 +43.14% ...